Professor, Medicine, University of Alabama School of Medicine
Gastroenterology
Dr. Peter Mannon, MD
|
|
Give Review
Peter Mannon works in the field of Gastroenterology. He researched medicine at Boston University School of Medicine. Boston University School of Medicine is ranked 30 in research and 52 in primary care medicine He received awards:"Regional Top Doctor". Peter Mannon is a published doctor and has 53 publications published. The lastest was: 'Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.' Peter Mannon accepts Medicare payments and is registered with Medicare.gov.
Publications
- Human seroreactivity to gut microbiota antigens.
- Characterization of Genetic Loci That Affect Susceptibility to Inflammatory Bowel Diseases in African Americans.
- Human gastric epithelial cells contribute to gastric Immune regulation by providing retinoic acid to dendritic cells.
- IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of Ulcerative colitis.
- Republished: Interleukin 13 and its role in gut defence and inflammation.
- Helicobacter pylori Infection Inhibits Phagocyte Clearance of Apoptotic Gastric Epithelial Cells.
- Interleukin 13 and its role in gut defence and inflammation.
- Angiotensin II regulates cellular Immune responses through a calcineurin-dependent pathway.
- Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon.
- Coagulation defects and altered hemodynamic Responses in mice lacking receptors for thromboxane A2.
- Peptide YY inhibits vasopressin-stimulated chloride secretion in inner medullary collecting duct cells.
- The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells.
- Total parenteral nutrition alters NPY/PYY receptor levels in the rat brain.
- Peptide YY receptor distribution and subtype in the kidney: effect on renal hemodynamics and function in rats.
- Distribution of binding sites for thromboxane A2 in the mouse kidney.
- Retinoic acid is a negative regulator of the neuropeptide Y/peptide YY Y1 receptor gene in SK-N-MC cells.
- Localization and characterization of neuropeptide Y/peptide YY receptors in the brain of the smooth dogfish (Mustelis canis).
- Diagnostic utility of K-ras mutational analysis on bile obtained by endoscopic retrograde cholangiopancreatography.
- Characterization of peptide YY receptors in rabbit colonic mucosa.
- Some sensory neurons express neuropeptide Y receptors: potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injury.
- Characterization of a Y1-preferring NPY/PYY receptor in HT-29 cells.
- Regulation of blood pressure by the type 1A angiotensin II receptor gene.
- Neuropeptide Y/peptide YY receptor binding sites in the heart: localization and pharmacological characterization.
- Cross-linking of neuropeptide Y to its receptor on rat brain membranes.
- Comparison of the neuropeptide Y receptor in the rat brain and intestine.
- Solubilization of the neuropeptide Y receptor from rat brain membranes.
- Successful granulocyte-colony stimulating factor treatment of Crohn''s Disease is associated with the appearance of circulating interleukin-10-producing T cells and in...
- Human primary gastric dendritic cells induce a Th1 Response to H. pylori.
- Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels.
- Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor.
- Peptide YY administration decreases brain aluminum in the Ts65Dn Down Syndrome mouse model.
- Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity.
- Inflammatory bowel Diseases: emerging therapies and promising molecular targets.
- Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn''s Disease.
- Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments.
- The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.
- Environmental triggers, genetic background, and Crohn's Disease.
- Suppression of inflammation in Ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production.
- Gut permeability and colitis.
- Multiple endoscopic biopsies in research subjects: safety results from a National Institutes of Health series.
- Extracorporeal photopheresis for the treatment of refractory Crohn''s Disease: results of an open-label pilot study.
- A common barrier defect for celiac Disease and ulcerative colitis.
- Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.
- Anti-IgE treatment of eosinophil-associated gastroIntestinal disorders.
- GAIN for loss: adalimumab for infliximab-refractory Crohn Disease.
- The fundamental basis of inflammatory bowel Disease.
- Excess IL-12 but not IL-23 accompanies the inflammatory bowel Disease associated with common variable immunodeficiency.
- Intestinal Disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype.
- Both IL-12p70 and IL-23 are synthesized during active Crohn's Disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
- Anti-interleukin-12 antibody for active Crohn''s Disease.
- Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in Ulcerative colitis.
- Peptide YY as a growth factor for Intestinal epithelium.
Schools
Boston University School Of Medicine
Duke University Med Center
Johns Hopkins Hospital
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
Conditions Treated
- Abdominal Pain
- Anemia
- Benign Neoplasm of the Digestive System
- Cholecystitis and Gallstones
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Aetna
- Blue Card PPO
- Dental Blue 100/200/300
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- Mutual of Omaha
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
Education
-
Duke University Hospital -
Johns Hopkins University -
Boston University School of Medicine
Hospital
-
University of Alabama Hospital -
Birmingham Veterans Affairs Medical Center -
Duke University Hospital
Drug Facts
| NPI NUMBER | 1528280997 | |
| NPPES Provider LastName | MANNON | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 352491900 | |
| NPPES Provider State | AL | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 430.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528280997 |
| Last Name Of The Provider | MANNON |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Julian W. Anderson, MD |
|
|
Dr. Basem Alkurdi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison D. Bridges, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles S. Bluhm, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David J. Landy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Owen R. McLean, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph T. Lyerly III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanette N. Keith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cregan J. Laborde, MD
This Doctor is OpenDoctor Recommended.
|